Pharma & Biotech Global Week in Review 25 Jan 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Algivon – UK: EWCA (Civ): Wise after the event: does expert evidence induce hindsight?: Apimed Medical Honey v Brightwake (PatLit) (IPKat) (EPLAW)

Gemcitabine – France: Court of appeal upholds validity of process patent: Sandoz v Eli Lilly (EPLAW)

Clopidogrel / Aspirin – Netherlands: Court of Appeal for The Hague confirms invalidity for lack of inventive step: Sanofi Aventis v Ratiopharm (EPLAW)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Why do generic drugs have such tongue-twisting names? (Class 46)

Brazilian innovation: A patent success (BIOtechNOW)

EU: Just one SPC per patent? What the Court of Justice really said: Medeva (The SPC Blog) (The SPC Blog)

EU: Planting another seed – maybe another CJEU referral on the way (The SPC Blog)

Israel: Salvador Dali visits the Knesset – consideration of the bill to enable 18-month publication of patent applications (America-Israel Patent Law)

Norway: Borgarting Court of Appeal rules patent covers SAV 3-virus and is infringed: Pharmaq v Intervet International (EPLAW)

UK: Is it obvious how to apply “obvious to try”?: Omnipharm v Merial (Kluwer Patent Blog)

US: Former Sanofi chemist pleads guilty to extensive trade secret theft (Trading Secrets)

US: FDA sends user fee pacts to Congress; proposed Generic Drug User Fee Statute includes some unique provisions (FDA Law Blog)

US: Alnylam Pharmaceuticals files patent infringement suit against Tekmira Pharmaceuticals based on importation and sales of dsRNA formulations comprising SNALP (Patent Docs)

 

Products

Algivon – UK: EWCA (Civ): Wise after the event: does expert evidence induce hindsight?: Apimed Medical Honey v Brightwake (PatLit) (IPKat) (EPLAW)

Amrix (Cyclobenzaprine hydrochloride) – US: District Court Delaware: Cephalon ordered to pay Anchen’s attorney fees for maintaining suit despite having no evidence of infringement: In re: Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Orange Book Blog)

Angiomax (Bivalirudin) – US: The Medicines Company to get patent term extension (Patent Docs)

Clopidogrel / Aspirin – Netherlands: Court of Appeal for The Hague confirms invalidity for lack of inventive step: Sanofi Aventis v Ratiopharm (EPLAW)

Foltx / Folbic (vitamins B12, B6 and folic acid) – US: Pamlab files patent infringement suit against Viva Pharmaceuticals over manufacture and sale of folic acid products (Patent Docs)

Gemcitabine – France: Court of appeal upholds validity of process patent: Sandoz v Eli Lilly (EPLAW)

Hydrophilic sulfonamide derivatives – EU: T 1827/07 – A late Swiss (K’s Law)

PhosLo GelCaps (Calcium acetate) – US: Fresenius Medical Care files patent infringement suit against Nostrum in response to Para IV challenge (Patent Docs)

Pristiq XR (Desvenlafaxine) – US: Leap year and Hatch-Waxman – An unusual conundrum years in the making (FDA Law Blog)

Singulair (Montelukast sodium) – US: Merck Frosst files patent infringement complaint against Teva in response to Para IV certification (Patent Docs)

Tobi (Tobramycin) – US: ND Illinois denies Novartis motion to dismiss lawsuit they brought against Akorn, grants Akorn’s motion to amend answer to include claim for declaratory judgment of non-infringement (FDA Law Blog)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: